Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia.

Kishi T, Suzuki T, Sekiguchi H, Moriwaki M, Okuda A, Mekata T, Hattori M, Tsunoka T, Chekuri R, Musso GM, Fujita K, Iwata N.

Asian J Psychiatr. 2013 Feb;6(1):86-7. doi: 10.1016/j.ajp.2012.08.006. Epub 2012 Sep 30. No abstract available.

PMID:
23380329
2.

A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG.

J Clin Psychiatry. 2008 Feb;69(2):274-85.

PMID:
18232726
3.

Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.

Bobb VT, Jarskog LF, Coffey BJ.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):539-43. doi: 10.1089/cap.2010.2062. No abstract available.

PMID:
21186975
4.

[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].

Meder J, Debowska G, Lis J, Araszkiewicz A, Sierosławska K, Kolesaric A, Treuer T.

Psychiatr Pol. 2004 May-Jun;38(3):469-84. Polish.

PMID:
15199656
5.

High-dose olanzapine for treatment-resistant schizophrenia.

Roth BL.

J Clin Psychiatry. 2008 Feb;69(2):176-7. No abstract available.

6.

Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.

Takeuchi H, Suzuki T, Remington G, Watanabe K, Mimura M, Uchida H.

Psychiatry Res. 2014 Aug 15;218(1-2):244-6. doi: 10.1016/j.psychres.2014.04.019. Epub 2014 Apr 16.

PMID:
24768247
7.

Olanzapine and haloperidol for residual symptoms.

de Haan L, van Beveren N.

Am J Psychiatry. 2005 Jul;162(7):1392-3; author reply 1393. No abstract available.

PMID:
15994737
8.

Re: treatment noncompliance with orally disintegrating olanzapine tablets.

Citrome L.

Can J Psychiatry. 2004 Jun;49(6):412-3; author reply 413. No abstract available.

PMID:
15283540
9.

Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.

Caforio G, Di Giorgio A, Rampino A, Rizzo M, Romano R, Taurisano P, Fazio L, De Simeis G, Ursini G, Blasi G, Nardini M, Mancini M, Bertolino A.

J Clin Psychopharmacol. 2013 Dec;33(6):810-2. doi: 10.1097/JCP.0b013e3182a4ec77. No abstract available.

PMID:
24113675
10.

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D.

Am J Psychiatry. 2010 Feb;167(2):181-9. doi: 10.1176/appi.ajp.2009.07081221. Epub 2009 Dec 15.

PMID:
20008947
11.

Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.

Suarez D, Haro JM, Novick D, Perrin E, Ochoa S, Naber D.

Pharmacopsychiatry. 2009 Jul;42(4):135-40. doi: 10.1055/s-0028-1112127. Epub 2009 Jul 7.

PMID:
19585391
12.

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L.

J Clin Psychopharmacol. 2008 Aug;28(4):392-400. doi: 10.1097/JCP.0b013e31817e63a5.

PMID:
18626265
13.

The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr.

J Clin Psychopharmacol. 2003 Dec;23(6):668-71. No abstract available.

PMID:
14624201
14.

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.

Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.

J Clin Psychopharmacol. 2008 Dec;28(6):601-7. doi: 10.1097/JCP.0b013e31818aaf6c.

PMID:
19011427
15.

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.

Bhowmick S, Hazra A, Ghosh M.

Aust N Z J Psychiatry. 2010 Mar;44(3):237-42. doi: 10.3109/00048670903487134.

PMID:
20050717
17.

Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.

Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S.

J Clin Psychiatry. 2004 Nov;65(11):1525-30.

PMID:
15554767
18.

Olanzapine pamoate for the treatment of schizophrenia.

Naber D.

Expert Opin Pharmacother. 2011 Mar;12(4):627-33. doi: 10.1517/14656566.2011.553193. Epub 2011 Jan 22. Review.

PMID:
21254860
19.

Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.

Witte MM, Case MG, Schuh KJ, Ascher-Svanum H.

Curr Med Res Opin. 2012 Mar;28(3):315-23. doi: 10.1185/03007995.2012.657300. Epub 2012 Jan 31.

PMID:
22236137
20.

A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Ermilov M, Gelfin E, Levin R, Lichtenberg P, Hashimoto K, Javitt DC, Heresco-Levy U.

Schizophr Res. 2013 Nov;150(2-3):604-5. doi: 10.1016/j.schres.2013.09.018. Epub 2013 Oct 2. No abstract available.

PMID:
24094884

Supplemental Content

Support Center